Management of the patient receiving parenteral biologic therapy

Journal of Infusion Nursing

Volumn 29, Issue 2, 2006, Pages 63-71

  Vizcarra, Cora ^a,b   Belcher, Dulce ^a  

^a MCV and Associates Healthcare Inc   (United States)

^b National Council of Education for the Infusion Nurses Society   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BEVACIZUMAB; CETUXIMAB; CYTOKINE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOMODULATING AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC REACTION; ANKYLOSING SPONDYLITIS; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; BIOTECHNOLOGY; BLOOD DISEASE; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CARCINOMA; CONGESTIVE HEART FAILURE; CROHN DISEASE; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG INDICATION; DRUG USE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFECTION; INFLAMMATION; INJECTION SITE REACTION; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; LUPUS LIKE SYNDROME; LYMPHOMA; MEDICAL SPECIALIST; METASTASIS; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NURSING CARE; PATIENT ASSESSMENT; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; DRUG MONITORING; DRUG STORAGE; ECONOMICS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; NEOPLASM; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; ONCOLOGY NURSING; REIMBURSEMENT; RISK FACTOR;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BIOLOGICAL THERAPY; DRUG MONITORING; DRUG STORAGE; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASMS; NURSE'S ROLE; NURSING ASSESSMENT; ONCOLOGIC NURSING; PATIENT EDUCATION; REIMBURSEMENT MECHANISMS; RISK FACTORS;

EID: 33646166167     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200603000-00003     Document Type: Review

References (29)

1. Rieger PT. Biotherapy: A Comprehensive Overview. 2nd ed. Sudbury, Mass: Jones and Bartlett; 2001:3-37.
2. Herskovitz S. Payers' dilemma: looming costs for chronic conditions. Biotechnol Healthcare. 2005;April:29-34.
3. Oldham R. Cancer biotherapy: general principles. In: Oldham R, ed. Principles of Cancer Biotherapy. 3rd ed. Dordrecht, Netherlands: Kluwer Academic Press; 1998:39-50.
4. Medicinenet.com: Biologic therapy. Available at: http://www.medicinenet. com/biological_therapy/article.htm. Accessed May 18, 2005.
5. Mackay I. Science, medicine, and the future: tolerance and auto immunity. Br Med J. 2000;321:93-96.
6. Understanding autoimmune disease. Available at: http://www.niaid.nih.gov/ publications/autoimmune.htm. Accessed November 30, 2004.
7. American Medical Association. Monoclonal antibodies. Available at: http://www.ama-assn.org/ama/pub/article/4781-4661.html. Accessed August 30, 2004.
8. Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci. 2002;324:14-30.
9. American Cancer Society. Monoclonal antibody therapy. Available at: http://www.cancer.org/docroot/ETO/content/ ETO_1_4X_Monoclonal_Antibody_Therapy_Passive_Immunotherapy.asp?sitearea=ETO. Accessed June 10, 2005.
10. Vizcarra C. New perspectives and emerging therapies for immune-mediated inflammatory disorders. J Infus Nurs. 2003;26:319-325.
11. Olsen N, Stein M. New drug therapy for rheumatoid arthritis. N Engl J Med. 2004;350:2167-2179.
12. Feldmann M, Maini RN. Anti-TNF therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163-196.
13. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289-298.
14. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296(5573):1634-1635.
15. Infliximab (Remicade) product information. Horsham, Pa: Centocor; May 2005.
16. Adalimumab [Humira] product information. Abbott Park, Ill: Abbott Laboratories; July 2004.
17. Rituximab (Rituxan) product information. San Francisco, Calif: Genentech; January 2005.
18. Trastuzumab (Herceptin) product information. San Francisco, Calif: Genentech; February 2005.
19. Gemtuzumab ozogamicin (Mylotarg) product information. Philadelphia: Wyeth Pharmaceuticals; April 2005.
20. Alemtuzumab (Campath) product information. Montville, NJ: Berlex; November 2004.
21. Ibritumomab tiuxetan (Zevalin) product information. Cambridge, Mass: Biogen Idec; January 2005.
22. Tositumomab and iodine I 131 tositumomab (Bexxar) product information. Research Triangle Park, NC. GlaxoSmithKline; March 2005.
23. Cetuximab (Erbitux) product information. San Francisco: Genentech; June 2004.
24. Bevacizumab (Avatin) product information. San Francisco: Genentech; January 2005.
25. The Health Assessment Questionnaire (HAQ) Disability Index and Pain Scale. Developed jointly by Stanford University Arthritis Center and the Arthritis, Rheumatism, and Aging Medical Information System, with funding support from the National Institutes of Health (NIH). 2003. Available at: http://aramis.standford.edu.
26. The Inflammatory Bowel Disease Questionnaire (IBDQ). Developed by the School of Nursing, Department of Clinical Epidemiology, and Biostatistics, and Department of Medicine, McMaster University, Hamilton, Ontario, Canada. 1999.
27. Estes J. Handling and disposal of monoclonal antibodies. Clin J Oncol Nurs. 2002;6(5):290-292.
28. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-1324.
29. Brower A. Today's leading product technologies. Biotechnol Healthcare. 2005;Feb:64.